Tuesday, December 6, 2011

American Society of Clinical Oncology issues annual report on progress against cancer

American Society of Clinical Oncology issues annual report on progress against cancer [ Back to EurekAlert! ] Public release date: 5-Dec-2011
[ | E-mail | Share Share ]

Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology

Report highlights the year's most significant developments in cancer research, policy

ALEXANDRIA, Va. The American Society of Clinical Oncology (ASCO) today released Clinical Cancer Advances 2011: ASCO's Annual Report on Progress Against Cancer, an independent review of the advances in cancer research that have had the greatest impact on patient care this year. The report also identifies the most promising trends in oncology and provides insights from experts on where the future of cancer care is heading.

"We've made significant strides in clinical cancer research over the past year and this report adds renewed hope for patients," said Nicholas J. Vogelzang, MD, Co-Executive Editor of the report. "More personalized treatment approaches and advances in early detection are helping patients live longer, healthier lives. But we must improve the nation's clinical research system and expand access to quality cancer care to accelerate the pace of progress."

This year's top research advances demonstrate new therapies for reducing cancer recurrence, progress made against hard-to-treat cancers, and improvements in cancer prevention and screening. The report also highlights several new drug approvals that bring smarter, more effective therapies to specific genetic subgroups of patients with cancer. The top five advances selected by the editors are:

  • A Phase III study finding that vemurafenib (Zelboraf), which targets a common mutation in melanoma in a gene called BRAF, improved overall survival in patients with advanced melanoma when compared to standard chemotherapy
  • A large national screening trial of more than 50,000 current and former heavy smokers that found three annual low-dose computed tomography (CT) scans reduced the death rate from lung cancer by 20 percent compared to those who were screened with three annual chest X-rays
  • FDA approvals on therapies for two hard-to-treat cancers:
    1. Crizotinib (Xalkori) was approved for patients with advanced non-small-cell lung cancer who harbor a specific type of alteration in the anaplastic lymphoma kinase (ALK) gene based on the results from two Phase II studies: one study demonstrated that 50 percent of patients experienced complete or partial tumor shrinkage for a median of 10 months and a second study found a 61 percent objective response rate lasting a median of 12 months
    2. Ipilimumab (Yervoy) an immune therapy that activates the immune system's T cells was approved for patients with previously untreated metastatic melanoma based on the results of a Phase III trial showing that the drug, combined with the standard chemotherapy drug dacarbazine, improved overall survival by two months
  • The first conclusive evidence that an aromatase inhibitor reduced the risk of a first breast cancer, making exemestane (Aromasin) a preventative treatment option for postmenopausal women who are at high risk for the disease.

Selected by an 18-person editorial board of prominent oncologists, the report highlights a total of 54 advances in clinical oncology over the past year and covers the full scope of patient care, including cancer disparities, advanced cancer care and survivor care. Clinical Cancer Advances 2011 also features a "Year in Review" section, which describes key cancer policy developments and ASCO policy initiatives from the past year that are likely to influence cancer care over the coming years. Some of the important topics covered in this section include:

###

To request a full copy of the Clinical Cancer Advances 2011 report, please contact Susie Tappouni at susie.tappouni@asco.org

About the Report

Clinical Cancer Advances was developed under the guidance of an 18-person editorial board made up of leading oncologists, including specialty editors for each of the disease- and issue-specific sections. Editors reviewed studies in peer-reviewed scientific journals and the results of research presented at major scientific meetings from October 2010 through September 2011. Only studies that significantly altered the way a cancer is understood or had an important impact on patient care were selected for the report. The report and additional resources will be posted on ASCO's patient Website at www.cancer.net/cca and will be published online in the Journal of Clinical Oncology on December 5.

About ASCO

The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who care for people with cancer. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org/presscenter. Patient-oriented cancer information is available at www.cancer.net


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


American Society of Clinical Oncology issues annual report on progress against cancer [ Back to EurekAlert! ] Public release date: 5-Dec-2011
[ | E-mail | Share Share ]

Contact: Susie Tappouni
susie.tappouni@asco.org
571-483-1355
American Society of Clinical Oncology

Report highlights the year's most significant developments in cancer research, policy

ALEXANDRIA, Va. The American Society of Clinical Oncology (ASCO) today released Clinical Cancer Advances 2011: ASCO's Annual Report on Progress Against Cancer, an independent review of the advances in cancer research that have had the greatest impact on patient care this year. The report also identifies the most promising trends in oncology and provides insights from experts on where the future of cancer care is heading.

"We've made significant strides in clinical cancer research over the past year and this report adds renewed hope for patients," said Nicholas J. Vogelzang, MD, Co-Executive Editor of the report. "More personalized treatment approaches and advances in early detection are helping patients live longer, healthier lives. But we must improve the nation's clinical research system and expand access to quality cancer care to accelerate the pace of progress."

This year's top research advances demonstrate new therapies for reducing cancer recurrence, progress made against hard-to-treat cancers, and improvements in cancer prevention and screening. The report also highlights several new drug approvals that bring smarter, more effective therapies to specific genetic subgroups of patients with cancer. The top five advances selected by the editors are:

  • A Phase III study finding that vemurafenib (Zelboraf), which targets a common mutation in melanoma in a gene called BRAF, improved overall survival in patients with advanced melanoma when compared to standard chemotherapy
  • A large national screening trial of more than 50,000 current and former heavy smokers that found three annual low-dose computed tomography (CT) scans reduced the death rate from lung cancer by 20 percent compared to those who were screened with three annual chest X-rays
  • FDA approvals on therapies for two hard-to-treat cancers:
    1. Crizotinib (Xalkori) was approved for patients with advanced non-small-cell lung cancer who harbor a specific type of alteration in the anaplastic lymphoma kinase (ALK) gene based on the results from two Phase II studies: one study demonstrated that 50 percent of patients experienced complete or partial tumor shrinkage for a median of 10 months and a second study found a 61 percent objective response rate lasting a median of 12 months
    2. Ipilimumab (Yervoy) an immune therapy that activates the immune system's T cells was approved for patients with previously untreated metastatic melanoma based on the results of a Phase III trial showing that the drug, combined with the standard chemotherapy drug dacarbazine, improved overall survival by two months
  • The first conclusive evidence that an aromatase inhibitor reduced the risk of a first breast cancer, making exemestane (Aromasin) a preventative treatment option for postmenopausal women who are at high risk for the disease.

Selected by an 18-person editorial board of prominent oncologists, the report highlights a total of 54 advances in clinical oncology over the past year and covers the full scope of patient care, including cancer disparities, advanced cancer care and survivor care. Clinical Cancer Advances 2011 also features a "Year in Review" section, which describes key cancer policy developments and ASCO policy initiatives from the past year that are likely to influence cancer care over the coming years. Some of the important topics covered in this section include:

###

To request a full copy of the Clinical Cancer Advances 2011 report, please contact Susie Tappouni at susie.tappouni@asco.org

About the Report

Clinical Cancer Advances was developed under the guidance of an 18-person editorial board made up of leading oncologists, including specialty editors for each of the disease- and issue-specific sections. Editors reviewed studies in peer-reviewed scientific journals and the results of research presented at major scientific meetings from October 2010 through September 2011. Only studies that significantly altered the way a cancer is understood or had an important impact on patient care were selected for the report. The report and additional resources will be posted on ASCO's patient Website at www.cancer.net/cca and will be published online in the Journal of Clinical Oncology on December 5.

About ASCO

The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who care for people with cancer. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org/presscenter. Patient-oriented cancer information is available at www.cancer.net


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2011-12/asoc-aso120511.php

ok state ok state kurt budke regis philbin regis and kelly reno fire regis philbin last show

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.